➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GLPG1690

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for GLPG1690?

GLPG1690 is an investigational drug.

There have been 9 clinical trials for GLPG1690. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.

The most common disease conditions in clinical trials are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Idiopathic Interstitial Pneumonias. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].

There are four US patents protecting this investigational drug and thirty-seven international patents.

Recent Clinical Trials for GLPG1690
TitleSponsorPhase
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic SclerosisGalapagos NVPhase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic SclerosisGalapagos NVPhase 2
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an InjectionGalapagos NVPhase 1

See all GLPG1690 clinical trials

Clinical Trial Summary for GLPG1690

Top disease conditions for GLPG1690
Top clinical trial sponsors for GLPG1690

See all GLPG1690 clinical trials

US Patents for GLPG1690

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GLPG1690   Start Trial Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE)   Start Trial
GLPG1690   Start Trial Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders Galapagos NV (Mechelen, BE)   Start Trial
GLPG1690   Start Trial Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE)   Start Trial
GLPG1690   Start Trial Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GLPG1690

Drugname Country Document Number Estimated Expiration Related US Patent
GLPG1690 Argentina 095280 2033-03-14   Start Trial
GLPG1690 Australia 2014231009 2033-03-14   Start Trial
GLPG1690 Australia 2017286828 2033-03-14   Start Trial
GLPG1690 Australia 2019204539 2033-03-14   Start Trial
GLPG1690 Brazil 112015020998 2033-03-14   Start Trial
GLPG1690 Canada 2902103 2033-03-14   Start Trial
GLPG1690 China 105143221 2033-03-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.